French cancer institute starts testing connected drug dispenser
THESS dispenser is equipped with an identity-vigilance system and warns patients when they need to take their treatment and verifies it has been delivered in accordance with the prescribed dose
A smart connected dispensing device that guarantees the packaging of pharmaceutical products and connects patients continuously to healthcare professionals in real time, while ensuring the correct dispensation of their prescribed doses, is being tested by a French cancer institute.
The Sainte-Catherine Cancer Institute in Avignon has announced its participation in the testing of the device, THESS (Therapy Smart System), being developed by French med-tech company La Valériane.
THESS is the result of five years of research by teams at La Valériane and fellow French company, SGH Healthcaring, which specializes in the manufacture of solutions for the administration of drugs. Useful for oral chemotherapy, the solution combines a smartphone-like dispenser with capsules containing the drugs.
The dispenser is equipped with an identity-vigilance system and the capsule is set up by the care teams and assigned to a patient. In addition, the distributor warns patients when they need to take their treatment and verifies that it has been delivered in accordance with the prescribed doses.
According to Roland Sicard, president of La Valériane, early monitoring has been ongoing for two months and THESS will be tested on 50 patients each from the Sainte-Catherine and Paoli-Calmettes institutes from February-March 2021.
In addition, experiments will also be conducted in two US cancer facilities under the supervision of the Georgia Tech Research Institute in Atlanta and are also expected to bring together 100 test patients.
“Other hospitals will be able to access the solution from July 2021,” Sicard said. "As part of our experiments, it is the healthcare institution that pays for all this. These are marginal costs that a hospital can bear and with these capsules that preserve the integrity of the drug, all those that have not been used will be recovered by the hospital.”
He added that if certain treatments and molecules display a real benefit in having this kind of technology to improve compliance or the right dosage, “one can imagine that the price of the smart pillbox is part of the price of the drug and sold with it. The payer would then be health insurance.”
He added that the dispensing machine costs the same as a mid-range smartphone, about EUR 400 to purchase or EUR 20 per month to rent,” explained Sicard. “The capsules cost between 2 and 3 euros each. For an oral treatment of four months, it takes four capsules, or 120 pills."
Medical studies show that for treatments with complex drugs, at risk of complications or for treatments whose effectiveness depends on fair compliance, a digital solution that facilitates patients’ remote monitoring significantly reduces complications and unscheduled hospitalizations while improving the efficacy of the treatment.
Founded in 2008 in Montpellier, La Valériane has so far invested EUR 5 million in THESS and is currently preparing a fundraiser of EUR 3-5 million in the coming months to continue their development.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance